Academia–pharma partnerships for novel drug discovery: <i>essential or nice to have?</i>

Palmer, Michelle; Chaguturu, Rathnam

doi:10.1080/17460441.2017.1318124

Cited by 33 publications

(16 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to the broadening horizon of pharmaceutical biotech specification, a cross-sectoral partnership is required for several reasons. The expertise of non-industrial partners could be fundamental to maintain the core activity of the business (Palmer & Chaguturu, 2017). Tailor-made treatments have become important in many health-related sectors (e.g.…”

Section: Key Partnersmentioning

confidence: 99%

Investigating the Current Business Model Innovation Trends in the Biotechnology Industry

Horváth

Khazami

Ymeri

et al. 2019

Journal of Business Economics and Management

View full text Add to dashboard Cite

The current trend of business model research shows an increased endeavour of conceptualizing business frameworks for circular economy (CE). While previous sustainability paradigms have failed to attract market stakeholders, their reaction differ regarding this concept. The reason is discovering that the benefits of former industrial systems have turned to be threats for modern companies. Thus, a circular transition seems beneficial not only in environmental but also in financial dimensions. Closing material and energy flows results in reduced costs and enables businesses to propose novel values to customers. The present study aims to investigate the current stage of circular transformation on a corporate level. In order to do that, it thoroughly analyses the business model evolution of an innovative and knowledge-intensive industry, biotechnology. The research employs a circular evaluation method to detect which parts of the applied business structures show the signs of transition. The findings indicate that the business innovation process in the sector is in line with the disciplines of CE. However, this phenomenon is rather the result of striving for market competitiveness, than making efforts for sustainable development. It proves the emergence of CE to be as much an economic concern as it is an environmental one.

show abstract

Section: Key Partnersmentioning

confidence: 99%

Investigating the Current Business Model Innovation Trends in the Biotechnology Industry

Horváth

Khazami

Ymeri

et al. 2019

Journal of Business Economics and Management

View full text Add to dashboard Cite

show abstract

“…More specifically, academia-pharma partnerships have the added benefit of maximising the strengths of the respective partners, integrating expertise in the technical field with knowhow to translate research findings into drugs. 30 Such partnerships may materialise through a variety of arrangements, including product development partnerships (PDPs), open innovation, public-private consortia, and joint ownership of laboratories. In fact, PDPs, which bridge public and private research entities with philanthropic and public funding, were the primary sponsor for 46% and 56% of new neglected disease drug approvals in the periods from 2000 to 2008 and 2009 to 2013, respectively.…”

Section: Discussionmentioning

confidence: 99%

Drug development for cryptococcosis treatment: what can patents tell us?

Santos-Gandelman

Machado-Silva

2019

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

BACKGROUND Cryptococcosis is one of the most devastating fungal infections in humans. Despite the disease’s clinical importance, current therapy is based on limited antifungals that are either toxic, inefficient, unavailable worldwide, or that quickly lead to resistance.OBJECTIVES The goal of this study was to provide insight into the future of cryptococcosis treatment by describing the patent scenario in this field.METHODS We identified and analysed patent documents revealing compounds with anti-cryptococcal activity supported by experimental evidence.FINDINGS Patenting in this field has been historically low, with an overall tendency of increase since 2012. Most applications are single filings, suggesting that they do not encompass strategic inventions requiring broad protection. Research and development essentially took place in China and the United States, which also represent the main countries of protection. Both academic and corporate institutions contributed to patenting in this field. Universities are the leading actors, with the highest patent family counts.CONCLUSION The low number of patents in this field indicates that efforts to mitigate the unmet needs for cryptococcosis treatment remain insufficient. Without investment to drive research and innovation, patients will likely continue to face inadequate assistance. Given the current scenario characterised by poor funding and low interest for technological development, drug repurposing may be the best alternative for cryptococcosis treatment.

show abstract

“…2,3 Large-scale collaborations between industry and academia, such as the Center for Biomedical Innovation (between Sanofi and MIT) and the Novo Nordisk Research Centre Oxford (between Novo Nordisk and the University of Oxford), have broad remits of advancing knowledge of human health, developing therapeutic applications and conducting translational research. [4][5][6] However, most collaborations are on a smaller-scale, involving an individual academic institute or Health Care Organization ("HCO") with a lead investigator, and relating to a specific study.…”

Section: Introductionmentioning

confidence: 99%

Practical considerations for collaborative research between the pharmaceutical industry and external investigators

Lloyd

Barbitsch

Hirsch

et al. 2019

Preprint

View full text Add to dashboard Cite

Traditionally, clinical research has been conducted via either industry sponsored studies or non-industry investigator sponsored studies. Collaborative Research provides a relatively new mechanism for industry and non-industry partners to work together in the pursuit of effective and safe treatments for the patient. The aims of this article are to provide both industry and non-industry investigators with a greater insight into the complex processes that are currently employed by industry when entering into Collaborative Research agreements, and to encourage consistency and transparency in approach across companies. In Collaborative Research, instead of being limited to providing funding and/or product, the industry partner contributes expertise complementary to that of the non-industry partner, who is the sponsor of the study. Collaborative Research may be conducted before, during or after regulatory approval of a drug or medical device, and may be interventional, observational or preclinical. A collaboration requires appropriate process and governance frameworks to be established in order to be successful. Important considerations include the routes for submitting a request, the review and approval process, due diligence criteria, budgeting and contracting processes, permissible interactions during the execution of the research, the closing out of the research, and dispute resolution. It is also necessary to have in place an agreed communication strategy and a risk control framework. Clear and specific contract language around roles and responsibilities, intellectual property, rights to data, registration and disclosure of publications, and an understanding of adverse event reporting procedures are other critical facets of Collaborative Research that are essential to avoid delays and disputes. With no global standards for Collaborative Research, it is important that partners establish practical procedures, good ongoing communication, alignment of goals, and transparent interactions and disclosure to jointly advance the science of new, safe and effective therapies.

show abstract

Academia–pharma partnerships for novel drug discovery: essential or nice to have?

Cited by 33 publications

References 10 publications

Investigating the Current Business Model Innovation Trends in the Biotechnology Industry

Investigating the Current Business Model Innovation Trends in the Biotechnology Industry

Drug development for cryptococcosis treatment: what can patents tell us?

Practical considerations for collaborative research between the pharmaceutical industry and external investigators

Contact Info

Product

Resources

About